MXCT Share Price Performance
UK£1.52
-1.76 (-53.66%)
68.8% undervalued intrinsic discount
UK£4.87
Fair Value
Price UK£1.52
AnalystConsensusTarget UK£4.87
Fair ValueUK£4.87
Share PriceUK£1.52
68.8% undervalued intrinsic discount
MXCT Community Narratives
AN
Fair Value UK£4.87 68.8% undervalued intrinsic discount
SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
MXCT Community Fair Values
- UK£4.87FV68.8% undervalued intrinsic discount17.54%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative5users have followed this narrativeabout 2 months ago author updated this narrative
Recent MXCT News & Updates
No updates
MaxCyte, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.39
- Gross Margin
- 80.91%
- Net Profit Margin
- -110.92%
- Debt/Equity Ratio
- 0%
MaxCyte, Inc. Competitors
About MXCT
- Founded
- 1998
- Employees
- 114
- CEO
- WebsiteView website
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading